NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

NCT04540406 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Suspected or Confirmed COVID-19

Interventions

DRUG: NBT-NM108
OTHER: Usual Care Only

Sponsor

Notitia Biotechnologies Company

Collaborators

[object Object]
[object Object]